Journal article
Erythropoietin in traumatic brain injury (EPO-TBI): A double-blind randomised controlled trial
A Nichol, C French, L Little, S Haddad, J Presneill, Y Arabi, M Bailey, DJ Cooper, J Duranteau, O Huet, A Mak, C McArthur, V Pettilä, M Skrifvars, S Vallance, D Varma, J Wills, R Bellomo
Lancet | ELSEVIER SCIENCE INC | Published : 2015
Abstract
Background Erythropoietin might have neurocytoprotective effects. In this trial, we studied its effect on neurological recovery, mortality, and venous thrombotic events in patients with traumatic brain injury. Methods Erythropoietin in Traumatic Brain Injury (EPO-TBI) was a double-blind, placebo-controlled trial undertaken in 29 centres (all university-affiliated teaching hospitals) in seven countries (Australia, New Zealand, France, Germany, Finland, Ireland, and Saudi Arabia). Within 24 h of brain injury, 606 patients were randomly assigned by a concealed web-based computer-generated randomisation schedule to erythropoietin (40 000 units subcutaneously) or placebo (0·9% sodium chloride sub..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The National Health and Medical Research Council and the Transport Accident Commission. EPO-TBI was supported by grants from the National Health and Medical Research Council of Australia (grant 545902) and the Transport Accident Commission of Victoria (grant D162). The members of the writing committee assume responsibility for the overall content and integrity of the article.